Hyperproduction of inhibitor-susceptible TEM β-lactamase is responsible for resistance of Serratia marcescens to β-lactam-β- lactamase inhibitor combinations

Chemotherapy

Volumn 54, Issue 1, 2007, Pages 31-37

  Zhao, Wei Hua ^a,b   Hu, Zhi Qing ^a   Chen, Gelin ^a   Ito, Ribu ^a   Shimamura, Tadakatsu ^a  

^a SHOWA UNIVERSITY HOSPITAL   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lactam; Lactamase inhibitor; Serratia marcescens; TEM lactamase

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CLAVULANIC ACID; ENZYME INHIBITOR; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CONJUGATION; BACTERIUM ISOLATION; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC CODE; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERRATIA MARCESCENS; WILD TYPE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; CLAVULANIC ACID; CONJUGATION, GENETIC; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PLASMIDS; POLYMERASE CHAIN REACTION; SERRATIA MARCESCENS;

EID: 37349127481     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112315     Document Type: Article

References (27)

1. Traub WH: Antibiotic susceptibility of Serratia marcescens and Serratia liquefaciens. Chemotherapy 2000;46:315-321.
2. Livermore DM: β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
3. Hashizume T, Sanada M, Nakagawa S, Tanaka N: Alteration in expression of Serratia marcescens porins associated with decreased outer membrane permeability. J Antimicrob Chemother 1993;31:21-28.
4. Kumar A, Worobec EA: Fluoroquinolone resistance of Serratia marcescens: involvement of a proton gradient-dependent efflux pump. J Antimicrob Chemother 2002;50:593-596.
5. Gutmann L, Chabbert YA: Different mechanisms of resistance to latamoxef (moxalactam) in Serratia marcescens. J Antimicrob Chemother 1984;13:15-22.
6. Hechler U, van den Weghe M, Martin HH, Frere JM: Overproduced beta-lactamase and the outer-membrane barrier as resistance factors in Serratia marcescens highly resistant to beta-lactamase-stable beta-lactam antibiotics. J Gen Microbiol 1989;135:1275-1290.
7. Livermore DM: Beta-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998;41(suppl D):25-41.
8. Kim J, Lim YM: Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol 2005;43:2452-2455.
9. IMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995;39:824-829.
10. Raimondi A, Sisto F, Nikaido H: Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob Agents Chemother 2001;45:2331-2339.
11. Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P: Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother 1994;38:1262-1270.
12. Datta N, Kontomichalou P: Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 1965;208:239-241.
13. Lahey Clinic: Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant β-lactamases. http://www.lahey.org/Studies/.
14. Bradford PA: Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951.
15. Ferrara A, Santos CD, Cimbro M: Effect of different β-lactams in combination with β-lactamase inhibitors in the presence or absence of tobramycin against some Enterobacteriaceae producing extended-spectrum β-lactamases. Chemotherapy 1998;44:313-317.
16. Chaibi EB, Sirot D, Paul G, Labia R: Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999;43:447-458.
17. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 5. Approved standard M7-A5. Wayne, National Committee for Clinical Laboratory Standards, 2000.
18. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-2239.
19. Pitout JD, Thomson KS, Hanson ND, Ehrhardt AF, Moland ES, Sanders CC: β-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob Agents Chemother 1998;42:1350-1354.
20. IMP. Antimicrob Agents Chemother 1995;39:1612-1615.
21. O'Callaghan CH, Morris A, Kirby SM, Shingler AH: Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother 1972;1:283-288.
22. Zhao W-H, Hu Z-Q, Hara Y, Shimamura T: Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:2266-2268.
23. Zhao W-H, Asano N, Hu Z-Q, Shimamura T: Restoration of antibacterial activity of β-lactams by epigallocatechin gallate against β-lactamase-producing species depending on location of β-lactamase. J Pharm Pharmacol 2003;55:735-740.
24. Rasmussen BA, Bush K: Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 1997;41:223-232.
25. Nikaido H, Vaara M: Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985, 49:1-32.
26. Weindorf H, Schmidt H, Martin HH: Contribution of overproduced chromosomal β-lactamases and defective outer membrane porins to resistance to extendedspectrum β-lactam antibiotics in Serratia marcescens. J Antimicrob Chemother 1998;41:189-195.
27. Kumar A, Worobec EA: Cloning, sequencing, and characterization of the SdeAB multidrug efflux pump of Serratia marcescens. Antimicrob Agents Chemother 2005;49:1495-1501.